Inovio Pharmaceuticals (INO) Other Working Capital Changes (2017 - 2022)
Inovio Pharmaceuticals (INO) posted Other Working Capital Changes of -$9.0 million for Q3 2022, down 200.85% sequentially from $9.0 million in Q2 2022, and down 31382.44% YoY from N/an in Q3 2021.
Inovio Pharmaceuticals (INO) Other Working Capital Changes (2017 - 2022) Analysis & Trends
Inovio Pharmaceuticals has reported Other Working Capital Changes for 6 years, with the latest figure at -$9.0 million in Q3 2022.
- Quarterly Other Working Capital Changes fell 31382.44% year-over-year to -$9.0 million in Q3 2022, while the trailing twelve-month figure through Jun 2023 was -$9.0 million (down 201.97% YoY) and the FY2022 annual result came in at -$85989.0, down 115.77% from the prior year.
- Other Working Capital Changes fell to -$9.0 million in Q3 2022 per INO's latest filing, from $9.0 million in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $39.3 million in Q2 2023 and troughed at -$39.3 million in Q1 2023.
- A 5-year average of -$2.6 million and a median of -$184616.0 in 2025 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 7290.35% in 2022, down 31382.44% in 2022.
- Over 5 years, Other Working Capital Changes stood at -$10091.0 in 2018, then plunged by 259.69% to -$36296.0 in 2019, then advanced by 19.45% to -$29238.0 in 2020, then plunged by 105.09% to -$59964.0 in 2021, then tumbled by 14974.97% to -$9.0 million in 2022.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$9.0 million, $9.0 million, and -$9963.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -9.04 Mn |
| Sep 30, 2022 | -9.04 Mn |
| Sep 30, 2022 | -9.04 Mn |
| Jun 30, 2022 | 8.96 Mn |
| Jun 30, 2022 | 8.96 Mn |
| Jun 30, 2022 | 8.96 Mn |
| Mar 31, 2022 | -9,963.00 |
| Mar 31, 2022 | -9,963.00 |
| Mar 31, 2022 | -9,963.00 |
| Dec 31, 2021 | -59,964.00 |
| Dec 31, 2021 | -59,964.00 |
| Dec 31, 2021 | -59,964.00 |
| Sep 30, 2021 | -28,713.00 |
| Sep 30, 2021 | -28,713.00 |
| Sep 30, 2021 | -28,713.00 |
| Jun 30, 2021 | 121,287.00 |
| Jun 30, 2021 | 121,287.00 |
| Jun 30, 2021 | 121,287.00 |
| Mar 31, 2021 | -72,463.00 |
| Mar 31, 2021 | -72,463.00 |